Moderna mRNA flu vaccine to get FDA panel review
Moderna’s experimental mRNA flu shot will be reviewed by a Food and Drug Administration (FDA) advisory panel next month, a move that suggests a more stable approach to drug reviews after the firing of former agency head Marty Makary. The panel will meet June 18 to discuss and make recommendations on the safety and effectiveness of Moderna’s MFLUSIVA flu vaccine, according to a Federal Register notice published…
Moderna’s experimental mRNA flu shot will be reviewed by a Food and Drug Administration (FDA) advisory panel next month, a move that suggests a more stable approach to drug reviews after the firing of former agency head Marty Makary. The panel will meet June 18 to discuss and make recommendations on the safety and effectiveness of Moderna’s MFLUSIVA flu vaccine, according to a Federal Register notice published…
Moderna’s experimental mRNA flu shot will be reviewed by a Food and Drug Administration (FDA) advisory panel next month, a move that suggests a more stable approach to drug reviews after the firing of former agency head Marty Makary. The panel will meet June 18 to discuss and make recommendations on the safety and effectiveness of Moderna’s MFLUSIVA flu vaccine, according to a Federal Register notice published…
The full story continues on The Hill.
Story Sentry shows a short summary aggregated via RSS. The complete article — original photography, charts, and reporting — lives with the publisher.